brain tumors: Microwave News Article Archive (2004 - )

The incidence of glioblastoma multiforme, GBM, the most aggressive type of brain tumor, though rising slowly over the last 20 years, has not jumped up in the U.S. and Canada, as it has in England and a number of other northern European countries, according to a new analysis of national brain tumor registry data.

Between 1995 and 2015, GBM rates went up 10% in the U.S. and 26% in Canada. In contrast, the increase in England over the same period was 110%.

It has been nearly eight years since an expert panel of the International Agency for Research on Cancer (IARC) classified RF radiation as a possible human carcinogen. Since then, neither the World Health Organization (WHO) nor the International Commission on Non-Ionizing Radiation Protection (ICNIRP) has recommended precautionary policies to limit potential health risks.

No U.S. health agency has yet advised the public to reduce RF exposures.

Even after two large animal studies —by the U.S. National Toxicology Program (NTP) and Italy’s Ramazzini Institute— presented clear evidence of a cancer link last year, the WHO has remained silent; ICNIRP responded by calling both animal studies unconvincing.

Now comes the Annual Review of Public Health, which on January 11 posted a paper by five leading epidemiologists who posit that, after a systematic review of all the human studies, they don’t see an elevated cancer risk. The takeaway is that the IARC classification was a mistake.

“Mobile Phone Use and Incidence of Brain Tumour Histological Types, Grading or Anatomical Location: A Population-Based Ecological Study,” BMJ Open, posted December 9, 2018.

“We found no evidence that mobile phone use increased any brain tumour histological types or subtypes.” See also the press release. Open access.

“Occupational Exposure to High-Frequency EMFs and Brain Tumor Risk in the INTEROCC Study: An Individualized Assessment Approach,” Environment International, online July 31, 2018.

“In conclusion, despite the improved quantitative exposure assessment used in this study, the results do not support a positive association between occupational exposure to high-frequency EMF and either glioma or meningioma risk. However, given our limited statistical power, due to the small number of exposed participants, and despite our results’ lack of significance our findings foster the need for further research focusing on RF magnetic fields and tumor promotion, as well as possible interactions with other frequencies and with chemicals.” (see press release.)

“Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial,” JAMA, December 19, 2017.

Supplementing chemotherapy with 200 kHz E-fields increased progression-free survival (by 2.7 months to 6.7 months) and overall survival (by 4.9 months to 20.9 months) in patients with newly diagnosed glioblastoma. Both are statistically significant improvements.

“Case-Control Study on Occupational Exposure to ELF EMFs and Glioma Risk,” American Journal of Industrial Medicine, posted online April 10, 2017.

“An increased risk in late stage (promotion/progression) of astrocytoma grade IV for occupational ELF-EMF exposure was found.” From Sweden (including Lennart Hardell). For background, see our “EMF Cancer Promotion: An Old Idea Makes a Strong Comeback.”

“Brain Cancer Patients Survive Longer By Sending Electric Field Through Their Heads,” IEEE Spectrum, November 22, 2016.

Novocure’s 200 kHz signals kept 43% of GBM patients alive compared to 30% on the standard treatment.

Senior managers at the National Toxicology Program (NTP) released the preliminary results of their cell phone radiation study late last week. They were so concerned about the elevated rates of two types of cancer among exposed rats that they felt an immediate public alert was warranted. They considered it unwise to wait for the results to wend their way into a journal sometime next year. Not surprisingly, the NTP report generated worldwide media attention.

There were some startling reactions. Both the American Cancer Society (ACS) and Consumer Reports immediately shelved their long-held, wait-and-see positions. In a statement issued soon after the NTP’s press conference, Otis Brawley, ACS’ chief medical officer, called the NTP report “good science.” Consumer Reports said that the new study was “groundbreaking” and encouraged people to take simple precautions to limit their exposures.

However, much of the mainstream media saw it very differently. The Washington Post ran its story under the headline, “Do Cell Phones Cause Cancer? Don’t Believe the Hype.”

“Scalp Device Might Help Patients with Brain Tumors,” Boston Globe, December 27, 2014.

The latest on NovoCure’s EM therapy for brain tumors. Not a cure; it increases overall survival time by about three months. The cost is high: $21,000/month. See also our other stories about NovoCure going back to 2007.